Table 2 Radiological, and laboratory data of the smoldering myeloma (group I) and multiple myeloma (group II) patients
From: Serum sclerostin and sympathetic skin response: relationship with myeloma bone disease
Group I (N = 35) | Group II (N = 35) | p value | |
|---|---|---|---|
Hemoglobin < 10 g/l | 2 (6%) | 15 (42%)* | 0.0005 |
Serum creatinine ≥ 2 mg/dl | 1 (3%) | 17 (49%)* | < 0.0001 |
Albumin < 3.5 gm/dl | 19 (54%) | 18 (51%) | 0.8 |
Serum β2 microglobulin > 3 mg/l | 18 (51%) | 21 (60%) | 0.4 |
Lactate dehydrogenase > 240 U/l | 7 (20%) | 15 (42%)* | 0.04 |
Serum sclerostin (ng/ml) | 0.52 (± 0.38) | 0.77 (± 0.37)* | 0.007 |
Myeloma bone disease | – | 35 (100%) |